Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Missed #LBRefresh Berlin? Check out our fireside chat with Peter of @casebiatx! #CRISPR #biotech https://t.co/brNNdzUyLD

Congratulations to CRISPR developer, Emmanuelle Charpentier and her colleagues for winning this year’s Kavli Prize in #Nanoscience. “for the invention of CRISPR-Cas9, a precise nanotool for editing DNA, causing a revolution in biology, agriculture, and medicine” @KavliPrize

See us on Twitter